Thalidomide to treat multiple myeloma


Few drugs, if any, have achieved the sad notoriety of thalidomide. Introduced in the late 1950s, it caused congenital birth defects in thousands of children worldwide and has been one of the most cautionary tales in the history of medicine. The medicine was banned at the beginning of the 1960s. During the years that followed, some beneficial effects of thalidomide were recognised for various disorders, and in Europe, since the ban, thalidomide has been used off-license and prescribed on a compassionate basis, mainly in hospitals.
In 2002, the European Medicines Agency (EMEA) received four marketing authorisation applications for thalidomide, which brought issues back to the surface. For the thalidomide victim associations, it was simply unacceptable that the drug be licensed again, and for the patient associations, it represented a major medical progress against their ailment.
As of 2006, however, no marketing applications had been authorised. Eurordis continued to work with all stakeholders to encourage marketing authorisation for thalidomide under strong safety guidelines.
For more information: Eurordis’ newsletter article - November 2006


La voix des patients atteints de maladies rares en EuropeEURORDIS Donnant la voix, à l'international, aux personnes vivant avec une maladie rare, Rare Diseases International est une initiative d'EURORDISRare Disease International Pour rapprocher patients, familles et experts sur un forum modéré multilingue, où partager leurs expériences. RareConnect est une initiative d'EURORDIS RareConnect Le programme Rare Barometer est une initiative d’EURORDIS qui vise à réaliser des sondages pour transformer les expériences des patients de maladie rare en faits et chiffres à communiquer aux décideurs politiques.Rare Barometer Campagne internationale de sensibilisation organisée chaque année le dernier jour de février, la Journée Internationale des Maladies Rares est une initiative d'EURORDISRare Disease Day Participez au plus grand événement réunissant tous les acteurs des maladies rares en Europe lors de Conférence européenne bisannuelle sur les maladies rares et les médicaments orphelins (European Conference on Rare Diseases and Orphan Products, ou ECRD). L'ECRD est une initiative d'EURORDISEuropean Conference on Rare Diseases